Nervous Disorder TRIZ Cases

A cyclic peptide with Arg-Trp-Thr structures binds to the Plexin protein.

Modified CD3-binding molecules cross-react with cynomolgus monkey CD3 while maintaining high affinity for human CD3, enabling effective preclinical testing.

Digestive enzymes alleviate neuropsychiatric symptoms, offering a safer alternative to antipsychotics with fewer side effects.

A peptide targeting N-type calcium channels reduces pain hypersensitivity without entering the central nervous system.

Heat-treating platelet pellet lysate at 55°C to 65°C removes fibrinogen-induced inflammation while preserving neurotrophic factors.

Topical mirtazapine formulation delivers active ingredient through skin to stimulate appetite in cats and dogs.

Specific delta opioid receptor modulating compounds treat neuropathic pain and depression.

Bromocriptine and topiramate combination therapy lowers amyloid beta pathology while avoiding side effects of secretase inhibitors.

A sublingual spray formulation delivers PDE5 inhibitors directly through the oral mucosa for rapid systemic uptake.

Human iPSC-derived neuronal screening isolates AAV capsids with high motor neuron tropism, resolving species-specific transferability gaps from animal models.

A uridine and cytidine composition reduces Nogo-A protein levels to improve hippocampus function.

Administering LSD to induce psychedelic states that assist psychotherapy, reducing anxiety and depression ratings beyond the acute drug effects.

Purified cannabidiol lowers seizure frequency in Dravet syndrome where standard anti-epileptic drugs fail to control symptoms.

Merging HMB anabolic effects with ketone body catabolic metabolism increases the lean-to-fat mass ratio while preventing muscle loss during fat reduction.

A pharmaceutical composition using Epimedium and Poria extracts improves learning and memory functions in senile dementia treatment.

Targeting the YLDFQ epitope on GM-CSFRα increases antibody potency, resolving insufficient inhibition of inflammatory tissue damage.

HCBI nucleotide sequences enable early detection of cancer and CNS diseases through specific viral component identification.

Sulfonylamide compounds target hyperphosphorylated tau aggregation, addressing the lack of effective treatments for Alzheimer's disease.

Adeno-associated viral vectors deliver NPC1 genes via tissue-specific promoters to reduce intracellular cholesterol accumulation in Niemann-Pick disease type C.

Placental growth factor induces GABAergic neuron differentiation to address insufficient nerve regeneration in autism and ADHD models.

STRO-1+ multipotential cells and their progeny modulate immune responses to treat inflammatory neurological diseases.

Segmenting calcitonin into a six-amino acid fragment eliminates teratogenic risks while preserving effective pain relief.

Merges desmopressin with an alpha-adrenergic receptor antagonist to reduce hyponatremia risk while treating nocturia.

Extracted heparin-binding domains inhibit syndecan-4 interactions, resolving complexity in identifying effective therapeutic agents for fibrosis and cancer.

Segmented immunogens provide broad antibody specificity that reduces brain drug concentrations and mitigates lethal overdose risks.

Soluble RGMc stabilizes blood brain barrier integrity to reduce immune cell infiltration, preventing neurological damage in multiple sclerosis models.

Engineered variant surface glycoproteins on trypanosomes display immunogenic compounds to resolve weak immune responses against small molecules.

Serum sphingolipid biomarkers detect nervonic acid absorption, resolving the contradiction between purity requirements and raw material availability.

Double-stranded oligonucleotides target expanded GAA mRNA to boost Frataxin expression without non-specific gene activation effects.

A peptide compound binds to the zinc-binding domain of amyloid beta peptides to prevent polymerization.

A unit dose formulation uses acid labile and alkalinizing coats to delay active substance release.

Monoclonal antibodies target the PAC1 receptor to reduce migraine frequency while avoiding side effects from broad-spectrum prophylactic therapies.

Cyclodextrin derivatives encapsulate nephrotoxic agents in hydrophobic cavities, lowering renal pathology scores while preserving therapeutic efficiency.

Pan-specific monoclonal antibodies stabilize non-toxic tau conformations, preventing intercellular transmission of pathogenic forms.

Adjusting the N/P ratio from high to low during sequential mRNA addition resolves the trade-off between delivery reliability and development time.

Buflomedil blocks OCT2 transporters to limit platinum drug uptake in healthy cells, reducing nephrotoxicity while preserving anti-tumor efficacy.

Intrathecally administered botulinum neurotoxin serotype A blocks glutamate release and reduces astroglial scarring to promote motor recovery.

Truncated hepcidin analogs mimic natural iron regulation by degrading ferroportin, reducing patient burden from invasive phlebotomy treatments.

Mammalized CDR-grafted antibodies reduce immune rejection while maintaining high potency against NGF.

Polyunsaturated free fatty acids bind to the GPR72 orphan receptor to activate signal transduction pathways.

Fused active restoration factors bind to collagen scaffolds via specific domains to retain cytokines at injury sites.

A fixed-dose pharmaceutical composition merges lacosamide and levetiracetam to deliver synergistic anticonvulsant activity.

Compounds of Formula I modulate eIF2B activity to restore translation initiation rates in cellular stress pathways.

Bimodal polyisobutylene maintains high permeation rates for seven days while preventing skin irritation and drug crystallization.

RNA aptamers inhibit AMPA receptors via SELEX-selected sequences, resolving poor water solubility and low specificity of conventional small molecule inhibitors.

Fermenting Perilla frutescens with microorganisms creates a composition that treats sleep disorders without drug dependence or side effects.